Compare Dollar Tree, Inc. (DLTR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Enveric Biosciences Inc — how do they compare? Dollar Tree, Inc. trades at $117.82 (market cap $22.26B), while Enveric Biosciences Inc trades at $1.44 (market cap $6.80M). The key difference: Dollar Tree, Inc. is far larger — about 3273.5× Enveric Biosciences Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Enveric Biosciences Inc for 14 Days on average.
| DLTR | ENVB | |
|---|---|---|
Market Cap | $22.26B | $6.80M |
Volume | 2,317,428 | 64,867 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $10.80 |
52-Week Low | $86.80 | $1.27 |
Typical Hold Time | 58 Days | 14 Days |
Enterprise Value | $28.87B | -$1.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $116.30, up 0.09% with a bullish technical signal despite bearish moving averages. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $2.70 beating expectations of $1.15. Revenue trends show recovery from 2025's $17.58B to projected $20.1B in 2026, while net income rebounds from -$3.03B to projected $1.6B. Analyst consensus is bullish with 53% buy ratings and $139.33 price target, representing 20% upside potential.
DLTR presents a compelling investment case with improving fundamentals and positive earnings momentum, though margin pressures and tariff volatility remain key risks. The stock's attractive valuation (P/E 14.54, EV/EBITDA 9.91) combined with strategic initiatives and store expansions support growth outlook, but investors should monitor cost inflation and competitive pressures in the discount retail sector.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
